advanc
clinic
virolog
detect
respiratori
virus
focus
nucleic
acid
amplif
techniqu
convert
refer
method
diagnosi
acut
respiratori
infect
viral
aetiolog
improv
current
commerci
molecular
assay
reduc
handsontim
reli
two
strategi
stepwis
autom
semiautom
complet
autom
whole
procedur
contribut
former
strategi
use
autom
nucleic
acid
extractor
multiplex
pcr
realtim
pcr
andor
dna
array
detect
amplicon
commerci
fullyautom
molecular
system
avail
detect
respiratori
virus
could
convert
pointofcar
method
substitut
antigen
test
detect
respiratori
syncyti
viru
influenza
b
virus
articl
describ
laboratori
method
detect
respiratori
virus
costeffect
ration
diagnost
algorithm
propos
consid
technic
aspect
avail
assay
infrastructur
possibl
laboratori
clinicepidemiolog
factor
infect
et
al
license
bentham
open
open
access
articl
licens
term
creativ
common
attribut
noncommerci
licens
http
permit
unrestrict
noncommerci
use
distribut
reproduct
medium
provid
work
properli
cite
acut
respiratori
infect
ari
viral
aetiolog
one
main
caus
morbid
mortal
worldwid
besid
classic
respiratori
virus
rv
ie
influenza
virus
flu
respiratori
syncyti
viru
rsv
human
rhinoviru
hrv
parainfluenza
viru
piv
adenoviru
adv
enteroviru
ev
human
coronaviru
hcov
new
rv
current
ad
list
human
metapneumoviru
hmpv
sarscov
hcov
human
bocaviru
hbov
other
rv
caus
benign
selflimit
infect
immunocompet
adult
howev
clinic
impact
ari
increas
affect
children
elderli
immunocompromis
individu
andor
subject
chronic
underli
diseas
rv
constitut
import
caus
hospitalis
mainli
cold
month
year
involv
import
cost
health
system
constitut
frequent
caus
school
work
absente
certain
circumst
emerg
rv
caus
great
impact
health
system
worldwid
occur
sarscov
flu
pandem
last
one
take
place
aetiolog
diagnosi
viral
ari
crucial
order
avoid
unnecessari
antibiot
use
establish
appropri
use
antivir
drug
comprehens
cohort
hospitalis
patient
minim
risk
nosocomi
transmiss
provid
epidemiolog
inform
earli
releas
recommend
prevent
address
correspond
author
servicio
de
hospit
universitario
virgen
de
la
niev
avda
fuerza
armada
granada
spain
tel
email
mercedesperezruizsspa
juntadeandalucia
treatment
final
reduc
overal
cost
deriv
manag
sever
diagnost
method
describ
rv
classifi
direct
detect
method
detect
viru
part
clinic
sampl
includ
viral
cultur
antigen
detect
method
molecular
techniqu
indirect
method
base
detect
immun
respons
viru
serolog
assay
clinic
practic
serolog
use
diagnosi
viral
infect
ari
caus
frequent
recurr
mainli
restrict
respiratori
mucosa
thu
case
direct
detect
viru
site
infect
prioriti
advanc
diagnost
virolog
detect
rv
focuss
nucleic
acid
amplif
techniqu
naat
sinc
sensit
tradit
method
viral
cultur
antigen
detect
assay
moreov
naat
avail
method
new
rv
grow
grow
poorli
cell
cultur
effici
antigen
detect
method
commercialis
naat
offer
addit
advantag
respect
classic
method
less
turnaround
time
less
effect
viru
viabil
effici
assay
contrari
disadvantag
attribut
naat
increas
reagent
cost
higher
handson
time
need
know
least
part
target
genom
design
appropri
primer
andor
probe
inde
mani
rv
rna
virus
subject
greater
genet
variabl
may
affect
sensit
reliabl
molecular
method
current
mani
commerci
molecular
assay
develop
allow
partial
complet
autom
procedur
semiautom
autom
assay
solv
part
one
disadvantag
naat
handson
time
mani
commerci
naat
requir
minim
manag
specimen
take
minut
increas
avail
easytoperform
multiplex
naat
detect
rv
costeffect
diagnost
algorithm
use
whether
less
complet
virolog
studi
carri
certain
patient
sampl
depend
resourc
type
laboratori
also
clinicepidemiolog
aspect
patient
age
sever
diseas
underli
condit
etc
articl
describ
molecular
method
use
detect
respiratori
virus
contribut
increas
autom
especi
molecular
assay
made
improv
laboratori
diagnosi
possibl
integr
new
assay
laboratori
portfolio
also
discuss
tradit
direct
method
rv
viral
cultur
antigen
detect
assay
among
indirect
method
mani
serolog
assay
eia
haemmagglutin
inhibit
complement
fixat
etc
use
rv
howev
serolog
use
clinic
practic
sinc
diagnosi
must
achiev
demonstr
seroconvers
seroincreas
igg
antibodi
acutephas
convalescentphas
serum
sampl
past
decad
viral
cultur
gold
standard
aetiolog
diagnosi
rv
autom
report
technolog
rather
advanc
field
clinic
virolog
focus
shorten
detect
time
increas
sensit
current
procedur
limit
refer
laboratori
provid
appropri
infrastructur
main
object
recov
viral
strain
genet
andor
antigen
characteris
tradit
viral
cultur
requir
least
day
yield
result
solv
problem
next
step
viral
cultur
methodolog
introduct
shellvial
assay
base
centrifugationenhanc
adsorpt
sampl
onto
cell
monolay
reproduc
cover
slip
detect
commonli
achiev
fluoresc
assay
monoclon
antibodi
cell
monolay
method
reduc
time
obtain
result
h
without
deleteri
effect
sensit
specif
although
viral
cultur
may
repres
open
system
detect
multipl
viral
pathogen
singl
cell
line
allow
growth
rv
rv
may
grow
cell
line
thu
detect
preval
rv
multipl
cell
line
must
use
combin
shellvial
assay
inclus
differ
cell
line
vial
repres
subsequ
step
facilit
recoveri
rv
isol
cell
cultur
naat
recent
contribut
increas
sensit
viral
cultur
pcr
assay
carri
cell
cultur
supernat
detect
isol
approach
demonstr
highest
sensit
read
procedur
allow
identifi
viral
isol
cell
monolay
cytopath
effect
howev
viral
cultur
use
detect
new
rv
sinc
grow
grow
poorli
cell
cultur
purpos
best
altern
naat
avail
monoclon
antibodi
allow
develop
differ
technolog
detect
viral
antigen
clinic
sampl
fluoresc
chromatograph
immunoassay
rapid
easi
perform
prove
util
mainli
rsv
flu
minimum
handson
handsoff
turnaround
time
techniqu
requir
obtain
result
convert
referr
pointofcar
diagnost
assay
howev
sensit
wide
depend
commerci
method
type
patient
sampl
rang
case
pandem
flu
higher
viral
load
thu
higher
sensit
antigen
detect
method
rsv
flu
observ
paediatr
popul
versu
adult
nasopharyng
aspir
versu
nasopharyng
exud
recent
goal
autom
type
diagnost
tool
achiev
new
commerci
assay
maripoc
respi
test
arcdia
turku
finland
allow
rapid
detect
differenti
viral
bacteri
respiratori
infect
flu
flu
b
rsv
hmpv
piv
adv
streptococcu
pneumonia
test
simpl
oper
handsontim
less
minut
per
sampl
result
highli
posit
sampl
obtain
minut
wherea
low
posit
neg
sampl
report
hour
maripoc
system
use
polystyren
microparticl
solid
phase
reaction
carrier
immunocomplex
format
viral
antigen
captur
specif
antibodi
fix
onto
microspher
bind
fluorescentlylabel
conjug
amount
immunocomplex
form
microspher
proport
analyt
concentr
detect
fluoresc
signal
carri
separationfre
twophoton
excit
fluoresc
detect
assay
arcdia
tm
tpx
tpx
contrast
antigen
detect
method
tpx
assay
avoid
need
multipl
wash
readout
achiev
onlin
monitor
reaction
kinet
preliminari
studi
report
sensit
specif
method
compar
ultrasensit
fluoresc
immunoassay
delphia
method
offer
advantag
autom
result
readout
allow
connect
laboratori
inform
system
naat
particularli
polymeras
chain
reaction
pcr
expand
rang
pathogen
identifi
clinic
laboratori
shown
util
clinic
diagnosi
viral
respiratori
infect
molecular
assay
greater
sensit
convent
method
viral
cultur
antigen
detect
inde
abl
detect
new
viral
agent
anoth
advantag
naat
compar
viral
cultur
requir
viabl
virus
thu
convert
gold
standard
detect
rv
thu
advanc
clinic
diagnost
virolog
made
naat
naat
especi
use
detect
lowposit
patient
yearli
period
rsv
flu
epidem
avail
naat
eas
manag
hospitalis
patient
control
outbreak
sinc
antigen
detect
test
sensit
enough
certain
popul
group
immunosuppress
individu
flu
hrv
piv
piv
piv
adv
hcov
except
sarscov
usual
caus
upper
respiratori
tract
infect
urti
wherea
rsv
hmpv
piv
frequent
associ
lower
respiratori
tract
infect
lrti
rv
rna
virus
except
adv
two
altern
feasibl
reversetranscript
rt
viral
rna
appropri
cdna
pcr
target
one
approach
use
random
andor
oligo
dt
primer
rt
step
subsequ
pcr
direct
rv
specif
primer
main
disadvantag
procedur
need
open
rt
tube
carri
pcr
onestep
rtpcr
protocol
report
elsewher
rna
virus
solv
problem
former
protocol
base
inclus
reaction
mix
reversetranscriptas
dna
polymeras
rt
pcr
step
enzym
reversetranscriptas
dna
polymeras
activ
monoplex
pcr
publish
commerci
kit
develop
detect
preval
rv
whether
simpler
complet
virolog
studi
must
carri
depend
mani
factor
sever
diseas
type
patient
capac
laboratori
avail
valid
optim
trademark
commerci
kit
number
sampl
laboratori
process
etc
nevertheless
mani
case
clinic
sign
symptom
ari
specif
singl
rv
mild
sever
infect
describ
virus
mention
current
monoplex
pcr
use
clinic
laboratori
equip
enough
conduct
extend
aetiolog
diagnosi
howev
advent
pandem
allow
mani
laboratori
equip
infrastructur
necessari
carri
pcr
assay
detect
pandem
flu
circumst
rapid
answer
encourag
monoplex
pcr
provid
effici
respons
multiplex
pcr
assay
wide
use
molecular
method
rv
detect
laboratori
clinic
virolog
capabl
develop
inhous
andor
robust
publish
protocol
advantag
respect
monoplex
pcr
cost
save
compar
multipl
monoplex
pcr
easier
process
run
inde
multiplex
pcr
extend
portfolio
virolog
diagnost
method
although
advantag
strong
enough
compens
disadvantag
multiplex
pcr
intrins
inconveni
number
target
increas
possibl
lose
sensit
specif
increas
well
due
competit
among
primer
viral
target
consequ
yield
unspecif
pcr
product
inde
multiplex
pcr
optim
ensur
adequ
amplif
viral
genom
multiplex
pcr
assay
demonstr
codetect
rv
sampl
common
event
whether
codetect
express
true
infect
virus
andor
prolong
shed
certain
agent
difficult
demonstr
although
author
point
role
codetect
rv
sever
diseas
tabl
show
import
advantag
disadvantag
differ
method
detect
rv
autom
molecular
assay
aim
continu
reduct
handson
time
yield
higher
reproduc
offer
possibl
detect
sever
pathogen
minimum
process
avail
autom
procedur
detect
rv
increas
day
day
oblig
virologist
choos
best
altern
take
account
laboratori
throughput
epidemiolog
clinic
costeffect
paramet
sinc
mani
instanc
commerci
assay
requir
apparatu
inde
commerci
diagnost
kit
less
versatil
often
expens
welloptim
inhous
pcr
molecular
procedur
achiev
autom
goal
rv
detect
could
divid
two
main
straightforward
phase
procedur
protocol
stepwis
autom
semiautom
fullyautom
naat
nucleic
acid
extract
readout
pcr
result
mani
effici
autom
system
cover
step
whole
procedur
emerg
last
year
chronolog
order
autom
extractor
realtim
pcr
instrument
dna
array
system
detect
pcr
product
recent
platform
nucleic
acid
purif
prepar
pcr
master
mix
main
contribut
semiautom
molecular
method
sever
commerci
assay
offer
autom
solut
nucleic
acid
extract
isol
purif
rang
low
high
throughput
high
qualiti
nucleic
acid
obtain
system
suitabl
broad
rang
applic
nucleic
acid
research
includ
gene
express
analysi
use
realtim
pcr
convent
pcr
standard
block
cycler
microarray
analysi
genotyp
reaction
mani
technolog
instrument
purifi
viral
dna
rna
broad
rang
respiratori
sampl
nasopharyng
aspir
swab
sputum
bronchoalveolar
lavag
contamin
reduc
sinc
system
close
avoid
splash
gener
aerosol
drop
mani
system
includ
readytorun
prefil
cartridg
reagent
requir
purif
procedur
setup
rapid
save
time
commerci
assay
simultan
process
maximum
sampl
avail
specif
studi
effici
method
recoveri
dna
rna
rv
carri
besid
higher
reproduc
amount
nucleic
acid
recov
autom
extract
method
greater
amount
achiev
manual
method
overal
good
recoveri
viral
rna
dna
without
signific
differ
among
autom
extractor
found
evid
presenc
inhibitor
observ
well
howev
studi
assess
wherea
instrument
yield
render
recov
dna
respiratori
pathogen
differ
reproduc
recoveri
linear
recov
viral
rna
paramet
consid
purif
rv
genom
extractor
must
versatil
allow
extract
wide
rang
respiratori
sampl
variabl
sampl
volum
inde
lysi
buffer
must
provid
independ
manufactur
inactiv
respiratori
specimen
biosafeti
cabinet
sampl
fed
open
contain
instrument
current
realtim
pcr
assay
wide
use
clinic
laboratori
principl
realtim
pcr
amplif
nucleic
acid
target
combin
simultan
detect
amplicon
singl
step
need
manipul
amplifi
product
minimis
contamin
due
amplicon
carryov
avoid
fals
posit
reaction
monitor
accumul
amplicon
real
time
achiev
label
primer
oligonucleotid
probe
amplicon
fluorophor
emit
fluoresc
signal
accumul
exponenti
phase
amplif
step
record
instrument
signal
relat
amount
amplicon
present
cycl
increas
amount
specif
amplicon
increas
variou
chemistri
use
realtim
pcr
assay
ie
taqman
probe
fret
probe
intercal
dye
sybr
green
molecular
beacon
scorpion
oligonucleotid
etc
commerci
assay
prodess
genprob
base
realtim
pcr
detect
sever
rv
receiv
fda
clearanc
kit
flu
type
subtyp
hmpv
adv
rsv
piv
detect
avail
realtim
pcr
use
dual
label
probe
taqman
probe
wide
use
virologist
hous
protocol
sinc
easi
optim
despit
higher
cost
compar
convent
pcr
protocol
reduct
handsontim
high
effici
compens
favour
use
approach
common
pcr
paramet
cycl
denatur
anneal
extens
appli
realtim
assay
protocol
carri
laboratori
rna
viru
includ
rv
flu
rsv
hrv
hmpv
hbov
hcov
use
instrument
protocol
person
commun
technic
disadvantag
realtim
pcr
limit
number
fluorophor
includ
singl
assay
thu
limit
multiplex
capabl
best
case
target
detect
singl
tube
publish
protocol
abl
detect
rv
multiplex
realtim
pcr
includ
tube
per
sampl
viral
target
per
tube
one
advantag
realtim
pcr
compar
newli
describ
protocol
possibl
quantit
role
high
viral
load
ari
provid
mani
circumst
valuabl
inform
optim
manag
treatment
infect
individu
preprepar
frozen
realtim
pcr
reagent
reduc
turnaround
time
increas
reproduc
frozen
aliquot
primersprob
mix
hand
gener
pcr
reagent
buffer
dntp
enzym
etc
good
altern
reduc
handsontim
pcr
prepar
step
emerg
amplif
procedur
describ
rv
detect
exampl
method
loopmedi
isotherm
amplif
multiplex
ligationdepend
probe
amplif
mlpa
padlock
probe
combin
pcr
hybridis
use
dna
array
principl
recent
develop
commerci
assay
rv
detect
depend
commerci
system
use
gener
multiplex
pcr
specif
detect
reli
array
luminex
xtag
rvp
first
panel
receiv
fda
approv
version
rvp
fast
shorten
initi
time
h
requir
accomplish
whole
procedur
rvp
fast
assay
incorpor
multiplex
rtpcr
use
primer
univers
tag
amplifi
product
hybrid
bead
array
conjug
specif
probe
detect
perform
use
streptavidinrphycoerythrin
conjug
bead
popul
detect
uniqu
viral
target
hybridis
specif
antitag
signal
median
fluoresc
intens
gener
bead
popul
fluoresc
valu
analyz
use
xtag
data
analysi
softwar
rvp
fast
tda
rvp
fast
establish
presenc
absenc
viral
target
sampl
recent
version
xtag
rvp
fast
panel
rvp
ce
mark
identifi
viral
type
subtyp
includ
flu
preliminari
evalu
rvp
demonstr
higher
recoveri
rv
specif
compar
inhous
realtim
pcr
competit
observ
sampl
spike
combin
rv
limit
detect
flu
rsv
calcul
replic
dilut
posit
sampl
semiquantit
viral
load
accomplish
measur
c
valu
observ
parallel
inhous
realtim
pcr
purpos
mean
c
obtain
origin
rtpcr
chosen
rvp
detect
rsv
dilut
sampl
detect
dilut
wherea
posit
inhous
pcr
reach
dilut
resplex
ii
qiagen
spectrum
aetiolog
diagnosi
xtag
rvp
detect
carri
similar
instrument
base
liquid
hybridis
former
main
differ
reli
amplif
system
qiaplex
technolog
involv
two
pair
genespecif
nest
primer
extrem
low
concentr
primer
use
initi
enrich
effici
amplif
mediat
superprim
univers
primer
bind
inner
nest
primer
pair
clinic
perform
studi
differ
popul
group
demonstr
good
result
rv
detect
use
system
autom
detect
format
use
rv
naat
respifind
assay
pathofind
seeplex
seegen
detect
viral
pathogen
respiratori
sampl
former
base
multiplex
rtpcr
follow
mlpa
reaction
compris
probe
hybrid
step
probe
ligat
step
probe
amplif
step
two
primer
use
final
pcr
everi
target
result
pcr
fragment
specif
length
seeplex
use
dualprim
oligonucleotid
allow
multiplex
pcr
high
specif
minim
possibl
unspecif
dna
product
detect
amplicon
accomplish
capillari
electrophoresi
assay
although
system
avoid
potenti
contamin
amplicon
abl
detect
wide
rang
rv
lower
cost
howev
specif
instrument
capillari
electrophoresi
avail
highthroughput
laboratori
recent
year
sever
autom
platform
nucleic
acid
purif
also
enabl
prepar
pcr
reaction
mix
micropl
readi
amplificationdetect
step
versant
kpcr
sampl
prep
system
siemen
qiasymphoni
qiagen
abbott
magnapur
roch
diagnost
exampl
platform
improv
reduc
even
handsontim
abolish
manual
step
associ
prepar
pcr
mix
evalu
system
demonstr
good
compar
perform
avail
fullyautom
naat
detect
less
number
rv
continu
increas
main
advantag
associ
use
tool
eas
use
minimis
handsontim
enclos
pouch
perform
reaction
step
minimum
contamin
risk
highord
multiplex
test
high
sensit
specif
reproduc
platform
focuss
autom
detect
rsv
andor
flu
probabl
attempt
constitut
futur
better
altern
antigen
detect
method
pointofcar
diagnosi
avail
commerci
fullyautom
assay
detect
flu
flu
b
andor
rsv
xpert
flu
cepheid
detect
flu
flu
b
differenti
simplexa
flu
ab
rsv
kit
focu
diagnost
detect
differenti
flu
flu
b
rsv
http
advantag
first
one
independ
modul
instrument
allow
continu
workflow
although
ad
modul
constitut
new
apparatu
increas
cost
later
use
cycler
integr
cycler
allow
simultan
process
respiratori
sampl
within
apparatu
nanospher
verigen
respiratori
viru
nucleic
acid
test
nanospher
recent
commercialis
fullyautom
assay
similar
previou
one
increas
diagnost
capabl
sinc
detect
differenti
flu
season
subtyp
flu
b
rsv
b
virus
inde
ad
innov
system
detect
mutat
within
neuraminidas
confer
resist
oseltamivir
studi
evalu
commerci
test
shown
optim
analyt
clinic
perform
filmarray
respiratori
panel
idaho
technolog
inc
commercialis
europ
fulli
autom
detect
identif
respiratori
pathogen
singl
sampl
one
hour
includ
virus
bacteria
unprocess
clinic
sampl
subject
nucleic
acid
purif
rt
highord
nest
multiplex
pcr
amplicon
melt
curv
analysi
close
dispos
pouch
larger
spectrum
panel
allow
addit
detect
respiratori
pathogen
may
advantag
diagnos
ari
popul
group
howev
detect
pathogen
lead
expens
system
assay
probabl
costeffect
rapid
detect
respiratori
agent
certain
clinic
sever
patient
tabl
display
list
commerci
fullyautom
assay
detect
identif
rv
recent
revis
molecular
assay
rv
carri
ginocchio
record
avail
autom
semiautom
commerci
test
optim
use
diagnost
tool
rv
detect
depend
correct
choic
method
combin
clinicepidemiolog
criteria
origin
sampl
patient
age
predispos
factor
sever
diseas
preval
specif
rv
certain
area
within
studi
period
must
consid
appropri
diagnost
algorithm
overwhelm
demand
rv
detect
clinic
sampl
evid
continu
sinc
advent
influenza
pandem
clinician
health
institut
realis
mani
circumst
aetiolog
diagnosi
ari
desir
thu
clinic
laboratori
must
take
account
point
avail
infrastructur
resourc
organis
workflow
portfolio
relat
diagnosi
viral
ari
ration
algorithm
viral
diagnosi
ari
could
divid
four
level
increas
use
diagnost
tool
depend
type
patient
overal
viral
diagnosi
outpati
mild
ari
probabl
costeffect
routin
perform
except
studi
surveil
program
epidemiolog
interest
antigen
detect
method
rsv
andor
flu
may
enough
patient
attend
emerg
unit
fulfil
sever
clinic
criteria
hospitalis
individu
constitut
except
protocol
pregnant
women
patient
sever
underli
condit
special
situat
immunosupress
obes
resid
chroniccar
facil
etc
extend
aetiolog
studi
andor
use
naat
preval
rv
encourag
accur
time
diagnosi
viral
ari
addit
benefit
prevent
unnecessari
use
antibiot
thu
decreas
overal
cost
treatment
minim
select
resist
organ
moreov
specif
antivir
therapi
recommend
treat
certain
risk
group
flu
rsv
infect
neuraminidas
inhibitor
recommend
patient
suspect
confirm
flu
requir
hospitalis
andor
highrisk
group
earli
treatment
neuraminidas
inhibitor
demonstr
decreas
risk
complic
reduc
durat
diseas
improv
outcom
ribavirin
approv
treatment
hospitalis
infant
young
children
immunocompromis
adult
sever
lower
respiratori
tract
infect
due
rsv
despit
limit
evid
benefit
new
autom
assay
may
improv
pointofcar
diagnosi
rv
sinc
includ
wider
rang
pathogen
within
kit
futur
autom
naat
may
altern
antigen
detect
method
cost
becom
compar
reduct
turnaround
time
achiev
sampl
patient
requir
hospitalis
neg
rsv
flu
antigen
result
subject
extend
virolog
studi
includ
viral
cultur
assay
andor
naat
target
less
rv
depend
sever
diseas
need
rapid
result
premis
naat
detect
rsv
flu
type
subtyp
level
patient
less
sever
ari
requir
admiss
intens
care
unit
icu
carri
first
otherwis
molecular
multiplex
method
low
complex
could
perform
certain
patient
includ
hmpv
hrv
piv
detect
depend
patient
age
andor
exist
underli
diseas
complex
naat
detect
less
frequent
rv
reserv
certain
situat
sever
case
icu
patient
previou
naat
preval
virus
yield
neg
result
level
autom
semiautom
naat
may
provid
higher
throughput
inhous
protocol
futur
feasibl
introduc
fullyautom
naat
wider
rang
health
institut
constitut
improv
viral
diagnosi
ari
basic
firstlevel
hospit
may
provid
well
effici
pointofcar
assay
ensur
appropri
manag
inpati
autom
field
clinic
virolog
diagnosi
ari
reli
molecular
assay
new
approach
yield
pointofcar
method
optim
rapid
detect
sever
rv
costeffect
laboratori
method
must
take
account
benefit
aetiolog
diagnosi
depend
technic
characterist
assay
avail
appropri
resourc
clinicepidemiolog
criteria
autom
naat
expens
probabl
costeffect
tool
sever
ill
hospitalis
patient
mani
autom
commerci
assay
requir
instrument
thu
laboratori
make
forecast
futur
provid
feasibl
autom
strategi
sinc
expertis
requir
carri
autom
molecular
assay
extend
aetiolog
diagnosi
ari
achiev
firstlevel
hospit
implement
techniqu
portfolio
